Skip to content
  • menu secondaire

    • Investors
    • Careers
    • Terms of Use
    • privacy policy
    • Cookie policy
    • Contacts
    • Profile
      • About Transgene
      • Management Team
      • Board of Directors
      • Scientific advisors
      • Corporate governance
      • Ethics & compliance
      • Collaborations
      • Partners
    • Technology
      • Viral-based Immunotherapies
        • Therapeutic Vaccines
        • Oncolytic Viruses
      • myvac Platform
      • Invir.IO Platform
      • Publications and Presentations
    • Portfolio
      • Pipeline
      • TG4050
      • TG4001
      • TG6002
      • TG6050
      • BT-001
      • Clinical trials FAQ
    • Press Releases
    • French

    Category: Press release

    Transgene Reports Third Quarter 2015 Financial Results

    20151021 PR US Q3 2015 FINAL

    Published 21 October 2015
    Categorized as 2015, Press release

    Transgene to Present at Ladenburg Thalmann 2015 Healthcare Conference in New York

    23092015 PR ladenburg conf_EN

    Published 23 September 2015
    Categorized as 2015, Press release

    Transgene Reports Financial Results for First Six Months of 2015 (interim report)

    20150910 – PR 2015 H1 results final

    Published 10 September 2015
    Categorized as 2015, Press release

    Transgene Announces Final Overall Survival Data from Phase 2b TIME Trial with TG4010 Immunotherapy in Non-Small Cell Lung Cancer Presented at World Conference on Lung Cancer

    20150908 PR TG4010 IASLC revised – BIS

    Published 8 September 2015
    Categorized as 2015, Press release, TG4010

    Transgene Announces Oral Presentation on TG4010 Cancer Immunotherapy at World Conference on Lung Cancer

    19 August 2015_PR_IASLC curtain raiser_ENG

    Published 19 August 2015
    Categorized as 2015, Press release, TG4010

    Transgene plans restructuring to focus on research and development

    20150629 PR 29 juin fin

    Published 29 June 2015
    Categorized as 2015, Press release

    Transgene Announces Positive New Results Presented at ASCO from Phase 2b TIME Trial with TG4010 Immunotherapy in Non-Small Cell Lung Cancer (poster)

    20150601 PR TG4010 TIME results_ASCO 2015_FINAL

    Published 1 June 2015
    Categorized as 2015, Press release, TG4010

    Transgene Announces Participation at Upcoming Investor Events

    20150518 May thru July 2015 IR events_ver 1 ENG

    Published 18 May 2015
    Categorized as 2015, Press release

    Transgene Presents New Data with TG1050, an Immunotherapy being Developed to Treat Chronic Hepatitis B, at The International Liver Congress™ 2015

    20150423 – US – EASL2015 TG1050

    Published 23 April 2015
    Categorized as 2015, Press release, TG1050

    Transgene Reports First Quarter 2015 Financial Results

    20150422 PR US Q1 2015

    Published 22 April 2015
    Categorized as 2015, Press release

    Posts navigation

    Newer posts Page 1 … Page 22 Page 23 Older posts
    • Investors
    • Careers
    • Terms of Use
    • privacy policy
    • Cookie policy
    • Contacts

    Transgene sa
    400 Boulevard Gonthier d’Andernach - Parc d'Innovation - CS80166
    67405 Illkirch Graffenstaden Cedex - France |
    Tel. : + 33 (0) 3 88 27 91 00

     

    © 2021 Transgene - All rights reserved
    Credits

    This Website uses cookies to provide you with the most relevant experience. By clicking on the "Accept All" button, you agree to the deposit of all cookies on your terminal. You can change your preferences or withdraw your consent at any time by clicking on the "Settings" button.
    More informationSettings Decline all ACCEPT ALL
    Cookies

    Privacy Overview

    This website uses cookies to improve your experience while you browse the website. Of these, cookies categorized as necessary are stored on your browser as they are essential for the functioning of basic functionalities of the website. We also use third-party cookies which advise us to analyze and understand how you use this website. These cookies will only be stored in your browser with your consent. You also have the option of deactivating these cookies. But disabling some of these cookies may affect your browsing experience.
    Necessary
    Always Enabled
    Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously. Analytical cookies used to understand how visitors interact with the website.
    Functional (video)
    Functional cookies help to perform certain functions such as sharing website content on social media platforms, collecting feedback and other third-party functionality.
    Third-party application cookies (twitter)
    Cookies déposés par des sociétés autres que Transgene. Ces cookies sont susceptibles de transmettre aux sociétés tiers des informations en lien avec les pages consultées. Ces sociétés doivent s’engager à garder ces données confidentielles dans le cadre de la loi informatique et libertés (6 janvier 1978).
    Save & Accept
    Powered by CookieYes Logo